Fig. 2
From: Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
Effects of siRNA mediated knockdown of CHK1, CHK2 or CHK1/2 on sensitivity to gemcitabine. a Effects of specific CHK1, CHK2, or both siRNAs compared to control siRNA (irrelevant) on CHK1 and CHK2 protein expression after 48 h transfection in VM-CUB1, RT-112 and T24 cells. b Effect of gemcitabine on cell viability in VM-CUB1, RT-112 and T24 cell lines after siRNA knockdown of CHK1, CHK2 or both CHK1/2 compared to irrelevant control. Note that for each siRNA treatment mean viability without gemcitabine was set as 1. c Relative cell viability in RT-112 and T24 cells was measured by MTT assay (mean ± SD, n = 4) after 48 h treatment with gemcitabine and/or Gö6976